Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Public offering by OxiGene nets $11mm

Executive Summary

OxiGene Inc. (developing vascular disrupting agents mainly for cancer) netted $11mm through the public sale of 5.9mm common shares at $2.05. The company also issued five-year warrants to purchase 2.9mm shares at $2.75. HC Wainwright was the placement agent.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies